TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01745302

Intervention type: DRUG
Intervention: TCM
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.

Intervention type: DRUG
Intervention: EGFR-TKI
Description: Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day

Intervention type: DRUG
Intervention: EGFR-TKI
Description: Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
Study: NCT03548792

Intervention type: RADIATION
Group type: OTHER
Intervention: RSA radiostereometric analysis
Description: Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical comparison
Description: ActivePAL, walking speed
Study: NCT02548364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol
Description: calcifediol treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control group
Study: NCT00710554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT00841074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: 0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Placebo mouthwash spray application of \~1.3 ml twice a day.
Study: NCT03705494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based peer counselling (web-based) intervention
Description: The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
Study: NCT01812304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hands-on training
Description: the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: frontal teaching
Description: one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
Study: NCT02911987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity training (HIT) program
Description: The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity training (HIT) program
Description: The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity training (HIT) program
Description: The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity training (HIT) program
Description: The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity training (MIT) exercise therapy
Description: MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
Study: NCT02486068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB scaffold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Study: NCT00021866

Intervention type: BEHAVIORAL
Intervention: Differential Abilities Scale
Description: IQ measurement at 3, 4.5 and 6 years of age

Intervention type: BEHAVIORAL
Intervention: Differential Abilities Scale
Description: IQ measurement at 3, 4.5 and 6 years of age

Intervention type: BEHAVIORAL
Intervention: Differential Abilities Scale
Description: IQ measurement at 3, 4.5 and 6 years of age

Intervention type: BEHAVIORAL
Intervention: Differential Abilities Scale
Description: IQ measurement at 3, 4.5 and 6 years of age

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Study: NCT00881829

Intervention type: DEVICE
Intervention: Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature
Description: Measurement of physiological parameters.
Study: NCT02085577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml
Description: Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride 0.9 percent
Description: Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Description: Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol 1 g
Description: Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 2 mg/ml
Description: Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 2 mg/ml
Description: Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual daily opioids
Description: The patients usual daily opioid consumption are administered during the study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual daily opioids
Description: The patients usual daily opioid consumption are administered during the study period
Study: NCT01052142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipovaxin-MM
Description: Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
Study: NCT02085577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
Study: NCT01210911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib
Description: Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
Study: NCT01935505

Intervention type: BEHAVIORAL
Intervention: Consulting
Description: The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.

Intervention type: BEHAVIORAL
Intervention: Consulting
Description: The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.

Intervention type: BEHAVIORAL
Intervention: Consulting
Description: The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.

Intervention type: DRUG
Intervention: Nicotine patch
Description: According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.

Intervention type: BEHAVIORAL
Intervention: Telephone intervention
Description: Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.

Intervention type: BEHAVIORAL
Intervention: Telephone intervention
Description: Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.

Intervention type: BEHAVIORAL
Intervention: Consulting+Telephone+Drug intervention
Description: Include all the above interventions
Study: NCT04721847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
Study: NCT02085577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microgram/ml
Description: Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil 5 microgram/ml
Description: Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
Study: NCT02414295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell injection
Description: Aspirated bone marrow then separation for Mesenchymal stem cell
Study: NCT00632593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Gastric Bypass
Study: NCT01520662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a secure web-based patient Wellness Portal
Description: Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
Study: NCT04560114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary.
Study: NCT03949231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1 inhibitor
Description: Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
Study: NCT02446366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03426488

Intervention type: BEHAVIORAL
Intervention: VIP - Västerbotten Intervention Programme
Description: Intervention on CVD (cardiovascular disease) and diabetes
Study: NCT04721847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
Study: NCT02446366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo hypofractionated SBRT
Study: NCT02454582

Intervention type: DEVICE
Group type: OTHER
Intervention: Somanetics INVOS Cerebral Oxymeter 5100C
Description: Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP

Intervention type: DEVICE
Group type: OTHER
Intervention: Somanetics INVOS Cerebral Oxymeter 5100C
Description: Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
Study: NCT02056288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
Study: NCT03715257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 14F staged extubation set guidewire
Description: 14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)
Study: NCT02056288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
Study: NCT00532857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Gemcitabine/Trastuzumab
Description: 80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
Study: NCT03715257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tube changing catheter
Description: Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)
Study: NCT03322137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNA-120
Description: Pegcantratinib ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNA-120
Description: Pegcantratinib ointment
Study: NCT00965094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (FK506)
Description: Capsules 0.5 mg, 1 mg. Dosing according to blood level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
Study: NCT03996460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 192 mg powder of K0706
Description: Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 384 mg powder of K0706
Description: Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
Study: NCT04228315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: radical cure dosing
Study: NCT03322137

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo ointment to mimic Pegcantratinib ointment
Study: NCT04228315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: radical cure dosing
Study: NCT04258098

Intervention type: DRUG
Intervention: Oral antibiotics ( Streptomycin ,metronidazole )
Description: Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.